Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings

Annals of Internal Medicine
Mayara Lisboa BastosDick Menzies

Abstract

Four months of rifampin treatment for latent tuberculosis infection is safer, has superior treatment completion rates, and is as effective as 9 months of isoniazid. However, daily medication costs are higher for a 4-month rifampin regimen than a 9-month isoniazid regimen. To compare health care use and associated costs of 4 months of rifampin and 9 months of isoniazid. Health system cost comparison using all health care activities recorded during 2 randomized clinical trials. (ClinicalTrials.gov: NCT00931736 and NCT00170209). High-income countries (Australia, Canada, Saudi Arabia, and South Korea), middle-income countries (Brazil and Indonesia), and African countries (Benin, Ghana, and Guinea). Adults and children with clinical or epidemiologic factors associated with increased risk for developing tuberculosis that warranted treatment for latent tuberculosis infection. Health system costs per participant. A total of 6012 adults and 829 children were included. In both adults and children, greater health system use and higher costs were observed with 9 months of isoniazid than with 4 months of rifampin. In adults, the ratios of costs of 4 months of rifampin versus 9 months of isoniazid were 0.76 (95% CI, 0.70 to 0.82) in high-inc...Continue Reading

References

Jun 3, 2004·American Journal of Respiratory and Critical Care Medicine·Dick MenziesKevin Schwartzman
Mar 21, 2009·American Journal of Respiratory and Critical Care Medicine·David P HollandJason E Stout
Dec 19, 2012·Annual Review of Public Health·Christopher DyeMario Raviglione
Jun 7, 2014·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·E GospodarevskayaS B Squire
Jan 24, 2016·BMC Health Services Research·Anete TrajmanGabriela B Gomez
Aug 2, 2017·Annals of Internal Medicine·Dominik ZennerMarieke J van der Werf
Feb 13, 2018·The International Journal of Health Planning and Management·Yisi LiuBeverley M Essue
Aug 2, 2018·The New England Journal of Medicine·Thierno DialloDick Menzies
Aug 2, 2018·The New England Journal of Medicine·Dick MenziesAndrea Benedetti
Feb 14, 2020·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·Timothy R SterlingRobert Belknap

❮ Previous
Next ❯

Citations

May 11, 2021·FEMS Microbiology Reviews·Andreu Coello PelegrinAlex van Belkum

❮ Previous
Next ❯

Software Mentioned

R
mratios in
R Project for Statistical Computing
SAS
NLESTIMATE

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.